Retrophin, Inc. (RTRX) was a big mover last session, as the company saw its shares rise by nearly 50% on the day. The move came on solid volume too with far more shares changing hands than in a normal session after the company signed a deal to acquire the privately held Manchester Pharmaceuticals and a drug prescribed off-label for a rare inherited disease. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.79 to $13.10 in the past one-month time frame.
The company has seen no estimate revision over the past 30 days, while the Zacks Consensus Estimate remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Retrophin currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Some other stocks worth considering in the BioTech sector include Alexion Pharmaceuticals, Inc. (ALXN), Gentium S.p.A (GENT) and Alimera Sciences, Inc. (ALIM). While Alexion and Gentium sport a Zacks Rank #1 (strong Buy), Alimera carries the same Zacks Rank as Retrophin.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment